Antibody Drug Conjugates

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for ADCs and its likely evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to ADCs, featuring brief description of ADCs, its components, mechanisms of action, and advantages over traditional targeted therapies. It also features a brief description of the absorption, distribution, metabolism and excretion (ADME) properties of various ADCs that are under development.

Chapter 4 provides information on 300 ADCs that are either approved or under development for the treatment of various indications. It features a detailed analysis of marketed / under development molecules, based on phase of development (marketed, phase III, Phase II/III, phase II, phase I/II, phase I, preclinical / discovery stage) of lead candidates, target antigen (CD30, HER2, CD22, CD33, and Others), type of linker used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), type of payload / warhead / cytotoxin (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), type of antibody (Anti-HER2, Anti-TROP2, Anti-CD30, Anti-mesothelin, Anti-CD22, and Others), antibody isotype (IgG, IgG1, IgG2, and IgG4), type of therapy (monotherapy and combination therapy), combination drug(s) (if being evaluated as combination therapy), target indication(s) (breast cancer, blood cancer, colorectal cancer, gastric cancer, gynecological cancer, head and neck cancer, lung cancer, and others), line of treatment (1st line, 2nd line, 3rd line, and Others), route of administration (intravenous and subcutaneous), and dosing frequency (Q1 weeks, Q2 weeks, Q3 weeks, Q4 weeks, and Others).

Chapter 5 presents elaborate profiles of companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios. Each profile features an overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.

Chapter 6 provides information on the most commonly targeted therapeutic indications and features brief description of the ADC candidates being developed against them. It highlights the key epidemiological facts about the diseases and currently available treatment options, other than ADCs.

Chapter 7 provides an analysis of KOLs in the field of ADCs. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with the information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The credibility and (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on number of publications, number of citations, number of clinical trials, number of affiliations, and extent of professional network.

Chapter 8 presents an insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved drug development efforts based on a singular target and geographical distribution of associated clinical trials.

Chapter 9 features an elaborate discussion and analysis of the various partnerships and collaborations that have been inked between various stakeholder in the industry, since 2014. Further, the partnership activity in this domain has been analyzed on the basis of year of agreement / partnership, the type of partnership model (R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, mergers and acquisitions, and others), companies involved, and regional distribution of the collaborations.

Chapter 10 presents details on various investments received by various players engaged in the development of ADCs. It also includes an analysis of the funding instances that have taken place in the market, till July 2021, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 11 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to ADCs. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 12 provides information on the various grants that were awarded to research institutes conducting projects related to ADCs, between 2016 and 2021. The analysis also highlights important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions and leading recipient organizations.

Chapter 13 provides a detailed analysis of completed, ongoing, and planned clinical studies of various ADCs, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target therapeutic area, and key geographical regions.

Chapter 14 presents an elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch and during / post launch. It also features an in-depth analysis and timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products. In addition, it provides a general overview of the drugs considered for studying the strategies in detail.

Chapter 15 highlights the key promotional strategies that are being implemented by the developers of marketed products, including POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA®, and ADCETRIS®. The promotional aspects covered in the chapter include details provided on the product website (including key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 16 features an overview of the various therapeutics being evaluated in combination with ADCs. It also features a study of the likely evolution of these therapeutics across different therapeutic indications.

Chapter 17 provides a review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations. In addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.

Chapter 18 provides an overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection. The chapter presents insights from recently conducted studies in different animal models, analyzing the different methods used in estimating FIH doses. In addition, it highlights possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD). The chapter highlights different types of ADC-related toxicities observed in animal models, highlighting the doses at which these toxicities were observed.

Chapter 19 highlights our views on the various factors that must be taken into consideration while deciding the prices of ADC products. It features discussions on different models / approaches that pharmaceutical companies may choose to adopt while deciding the prices at which their ADC products can be marketed. 

Chapter 20 provides details of the players that offer contract manufacturing services for ADCs, or possess the necessary capabilities and infrastructure to manufacture such products in-house. The chapter illustrates the manufacturing capabilities of different contract manufacturers highlighting their expansion plans and other agreements inked between companies.

Chapter 21 is a case study focused on the use of companion diagnostics in the field of ADCs. It provides a list of companies offering companion diagnostics for targets being targeted by ADCs, including information on their geographical location, affiliated biomarker, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidate(s) for which it is already available.

Chapter 22 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the ADCs market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 23 features an elaborate market forecast analysis, highlighting the likely growth of ADC market, till the year 2030. In order to provide details on future opportunity, our projections have been segmented on the basis of [A] target indication (Breast cancer, Blood cancer, Colorectal cancer, Gastric cancer, Gynecological cancer, Head and neck cancer, Lung cancer, and Others), [B] type of linker used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), [C] type of payload (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), [D] target antigens (CD30, HER2, CD22, CE33, and Others), and [E] key geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 24 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations with Christian Rohlff, (Founder and Chief Executive Officer, Oxford BioTherapeutics), Paul Jaminet (Founder and Chief Executive Officer, Angiex), Sasha Koniev (Co-Founder and Chief Executive Officer, Syndivia), Aldo Braca (President and Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals), John Burt (Chief Executive Officer, Abzena), Michael Schopperle (Chief Executive Officer, CureMeta), Anonymous (Chief Executive Officer, Leading CMO), Jeff Landau (Chief Business Officer and Head of Strategy, CytomX), Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai), Justin Oh (Executive Director, AbTis), Sukumar Sakamuri (Vice President and Head of Chemistry, AmbrX), Anonymous (Director, Business Development, Leading CMO), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (Director of CDMO, Pierre Fabre), Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Piramal Healthcare), Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services), and Alan Burnett (Professor, School of Medicine, Cardiff University).

Chapter 25 is the summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of the ADC therapeutics market.

Chapter 26 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 27 is an appendix, which contains a list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Anticancer Therapies 
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies

3.4. Monoclonal Antibody-Based Anticancer Therapies
3.5. Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker

3.6. Advantages of ADC Therapeutics Over Traditional Therapeutic Interventions
3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody-Based Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Elimination

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Antibody Drug Conjugates: Drug Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Linker
4.2.10. Analysis by Type of Payload / Warhead
4.2.11. Antibody Drug Conjugates: Distribution by Target Antigens and Target Disease Indications
4.2.12. Antibody Drug Conjugates Approved and Development Pipeline: Grid Analysis

4.3. Antibody Drug Conjugates: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Key Players: Analysis by Number of Therapies
4.3.5. Logo Landscape: Analysis by Target Disease Indication and Company Size
4.3.6. Technology Platforms
4.4. Novel Drug Conjugates

5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. Seagen
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview
5.2.3.1. Adcetris
5.2.3.2. Padcev
5.2.3.3. HuMax-TF
5.2.3.4. SGN-LIVIA
5.2.4. Recent Developments and Future Outlook

5.3. Roche / Genentech
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview
5.3.3.1. Kadcyla
5.3.3.2. Polivy
5.3.4. Recent Developments and Future Outlook

5.4. Pfizer
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. Mylotarg
5.4.3.2. Besponsa
5.4.4. Recent Developments and Future Outlook

5.5. AstraZeneca
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview
5.5.3.1. Enhertu
5.5.4. Recent Developments and Future Outlook

5.6. Astellas Pharma
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.4. Recent Developments and Future Outlook 

5.7. ImmunoGen
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview
5.7.3.1. Mirvetuximab Soravtansine
5.7.4. Recent Developments and Future Outlook 

5.8. Daiichi Sankyo
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview
5.8.3.1. Patritumab deruxtecan
5.8.3.2. Datopotamab deruxtecan
5.8.4. Recent Developments and Future Outlook

5.9. Gilead
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Pipeline Overview
5.9.3.1. Trodelvy
5.9.4. Recent Developments and Future Outlook

5.10. AbbVie
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Pipeline Overview
5.10.3.1. Telisotuzumab vedotin
5.10.3.2. ABBV-3373
5.10.4. Recent Developments and Future Outlook

5.11. Bayer
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Pipeline Overview
5.11.3.1. Anetumab ravtansine
5.11.4. Recent Developments and Future Outlook

5.12. RemeGen
5.12.1. Company Overview
5.12.2. Pipeline Overview
5.12.2.1. Disitamab vedotin
5.12.3. Recent Developments and Future Outlook

5.13. ADC Therapeutics
5.13.1. Company Overview
5.13.2. Pipeline Overview
5.13.2.1. Zynlonta
5.13.2.2. Camidanlumab tesirine
5.13.3. Recent Developments and Future Outlook

6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction and Epidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia

6.2.1.2. Lymphoma: Introduction and Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.3.1. Targeted Therapies
6.2.1.3.2. ADC Therapeutics for Leukemia / Lymphoma

6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADC Therapeutics for Multiple Myeloma

6.3. Solid Tumors
6.3.1. Lung Cancer
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADC Therapeutics for Lung Cancer

6.3.2. Breast Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADC Therapeutics for Breast Cancer

6.3.3. Ovarian Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADC Therapeutics for Ovarian Cancer

6.3.4. Bladder Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADC Therapeutics for Bladder Cancer

6.3.5. Colorectal Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADC Therapeutics for Colorectal Cancer

6.3.6. Prostate Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADC Therapeutics for Prostate Cancer

6.3.7. Gastric Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADC Therapeutics for Gastric Cancer

7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Methodology

7.3. Principal Investigators Involved in Clinical Trials
7.3.1. Geographical Distribution of Key Opinion Leaders
7.3.1.1. Experts on Adcetris
7.3.1.2. Experts on Kadcyla
7.3.1.3. Experts on Mylotarg
7.3.1.4. Experts on Other ADCs

7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring

7.6. Most Active Key Opinion Leaders
7.6.1. KOL Profile: KOL A (Celgene)
7.6.2. KOL Profile: KOL B (Georgetown University and Medical centre)
7.6.3. KOL Profile: KOL C (Cancer Hospital and Institute)
7.6.4. KOL Profile: KOL D (Comprehensive Cancer Centers of Nevada)

8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Key Clinical Targets for ADCs
8.4.1. Four-Dimensional Bubble Analysis
8.4.2. Five-Dimensional Spider Web Analysis

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Antibody Drug Conjugates: Funding and Investment Analysis
10.3.1. Analysis by Year of Investment
10.3.2. Analysis by Number of Funding Instances
10.3.3. Analysis by Amount Invested
10.3.4. High Value Deals: Analysis by Year of Investment
10.3.5. Analysis by Type of Funding

10.3.6. Most Active Players
10.3.6.1. Analysis by Number of Funding Instances
10.3.6.2. Analysis by Amount Invested

10.3.7. Most Active Investors: Analysis by Number of Instances
10.4. Concluding Remarks

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Antibody Drug Conjugates: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Geography
11.3.3. Analysis by CPC Symbols
11.3.4. Emerging Focus Areas
11.3.5. Analysis by Type of Organization
11.3.6. Leading Players: Analysis by Number of Patents
11.4. Antibody Drug Conjugates: Benchmarking Patent Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Antibody Drug Conjugates: Patent Valuation Analysis

12. ACADEMIC GRANTS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Antibody Drug Conjugates: List of Academic Grants
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Grant Amount Awarded
12.3.3. Analysis by Administering Institute Center
12.3.4. Analysis by Support Period
12.3.5. Analysis by Funding Institute Center and Support Period
12.3.6. Analysis by Type of Grant Application
12.3.7. Analysis by Purpose of Grant Award
12.3.8. Analysis by Activity Code
12.3.9. Emerging Focus Areas
12.3.10. Analysis by Study Section Involved
12.3.11. Popular NIH Departments: Analysis by Number of Grants
12.3.12. Analysis by Type of Recipient Organization
12.3.13. Prominent Program Officers: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Number of Grants
12.3.15. Regional Distribution of Recipient Organizations

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Antibody Drug Conjugates: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Phase
13.3.3. Analysis by Trial Recruitment Status
13.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
13.3.5. Analysis by Study Design
13.3.6. Analysis by Sponsor / Collaborator
13.3.7. Most Active Players: Analysis by Number of Registered Trials
13.3.8. Emerging Focus Areas
13.3.9. Analysis by Trial Phase and Target Disease Indication
13.3.10. Geographical Analysis by Number of Clinical Trials
13.3.11. Geographical Analysis by Number of Patients Enrolled

14. KEY COMMMERCIALIZATION STRATEGIES
14.1. Chapter Overview
14.2. Successful Drug Launch Strategy: ROOTS Framework
14.3. Successful Drug Launch Strategy: Product Differentiation
14.4. Common Commercialization Strategies Adopted Based on Development Stage of Product

14.5. Approved ADCs: An Overview
14.5.1. Adcetris
14.5.2. Kadcyla
14.5.3. Mylotarg
14.5.4. Besponsa
14.5.5. Lumoxity
14.5.6. Polivy

14.6. Key Commercialization Strategies Adopted by the Companies Developing Antibody Drug Conjugates
14.6.1. Strategies Adopted Before the Approval of Drug
14.6.1.1. Participation in Global Events
14.6.1.1.1. Adcetris
14.6.1.1.2. Kadcyla
14.6.1.1.3. Mylotarg
14.6.1.1.4. Besponsa
14.6.1.1.5. Lumoxiti
14.6.1.1.6. Polivy
14.6.1.2. Collaboration with External Stakeholders and Pharmaceutical Firms
14.6.1.2.1. Adcetris
14.6.1.2.2. Kadcyla
14.6.2. Strategies Adopted During / Post Approval of Drug
14.6.2.1. Geographical Expansion
14.6.2.1.1. Adcetris
14.6.2.1.2. Kadcyla
14.6.2.1.3. Besponsa

14.6.2.2. Participation in Global Events Post Product Approval
14.6.2.2.1. Adcetris
14.6.2.2.2. Kadcyla
14.6.2.2.3. Mylotarg
14.6.2.2.4. Besponsa
14.6.2.2.5. Lumoxiti

14.6.2.3. Awareness Through Product Websites
14.6.2.4. Collaboration with External Stakeholders and Pharmaceutical Firms
14.6.2.4.1. Adcetris
14.6.2.4.2. Lumoxiti
14.7. Concluding Remarks

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Brochure and Informative Downloads

15.5. Adcetris: Promotional Analysis
15.5.1. Product Website Analysis
15.5.1.1. Messages for Healthcare Professionals
15.5.1.2. Messages for Patients
15.5.2. Patient Support Services and Informative Downloads
15.5.3. Other Promotional Activities
15.5.3.1. Participation in Conferences

15.6. Kadcyla: Promotional Analysis
15.6.1. Product Website Analysis
15.6.1.1. Messages for Healthcare Professionals
15.6.1.2. Messages for Patients
15.6.2. Patient Support Services and Informative Downloads
15.6.3. Other Promotional Activities
15.6.3.1. Participation in Conferences

15.7. Mylotarg: Promotional Analysis
15.7.1. Product Website Analysis
15.7.1.1. Messages for Healthcare Professionals
15.7.1.2. Messages for Patients
15.7.2. Patient Support Services and Informative Downloads
15.7.3. Other Promotional Activities
15.7.3.1. Participation in Conferences

15.8. Besponsa: Promotional Analysis
15.8.1. Product Website Analysis
15.8.1.1. Messages for Healthcare Professionals
15.8.1.2. Messages for Patients
15.8.2. Patient Support Services and Informative Downloads
15.8.3. Other Promotional Activities
15.8.3.1. Participation in Conferences

15.9. Lumoxiti: Promotional Analysis
15.9.1. Product Website Analysis
15.9.1.1. Messages for Healthcare Professionals
15.9.1.2. Messages for Patients
15.9.2. Patient Support Services and Informative Downloads
15.9.3. Other Promotional Activities
15.9.3.1. Participation in Conferences

15.10. Polivy: Promotional Analysis
15.10.1. Product Website Analysis
15.10.1.1. Messages for Healthcare Professionals
15.10.1.2. Messages for Patients
15.10.2. Patient Support Services and Informative Downloads
15.10.3. Other Promotional Activities
15.10.3.1. Participation in Conferences

16. COMBINATION THERAPIES
16.1. Chapter Overview
16.2. Combination Therapy: History of Development

16.3. Combination Therapy: FDA Guidelines
16.3.1. Combinations of Marketed Drugs
16.3.2. Combinations of Marketed Drugs with New Molecular Entities
16.3.3. Combinations of New Molecular Entities 

16.4. Combination Therapies: ADCs
16.4.1. Completed / Ongoing Clinical Studies of ADCs
16.4.1.1. Analysis by Type of Therapy
16.4.2. Completed / Ongoing Clinical Studies of ADC-Based Combination Therapies 
16.4.2.1. Analysis by Highest Phase of Development
16.4.2.2. Analysis by Current Trial Status
16.4.2.3. Analysis by Type of Combination Therapy
16.4.2.4. Analysis by Target Disease Indication and Type of Combination Therapy

17. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
17.1. Chapter Overview
17.2. First Generation ADC Technologies

17.3. Second Generation ADC Technologies
17.3.1. Cysteine and Selenocysteine Engineering
17.3.2. Unnatural Amino Acid Engineering
17.3.3. Amino-Terminal Serine Engineering

17.4. Third Generation ADC Technologies
17.4.1. Enzyme-Assisted Ligation Approaches
17.4.2. Glycan Remodeling Approaches
17.4.3. Ligation at Fab Nucleotide-Binding Site
17.4.4. Cysteine Rebridging
17.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
17.5. Other Emerging ADC Technologies
17.6. Evolutionary Analysis

18. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
18.1. Chapter Overview
18.2. ADCs and Non-Clinical Studies
18.3. ICH S9 Guidelines
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.4.1. Example Case: Kadcyla

18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
18.7. Other Key Considerations for Study Design

19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of Antibody Drug Conjugates
19.3. Antibody Drug Conjugates Market: Pricing Models
19.3.1. On the Basis of Associated Costs
19.3.2. On the Basis of Competition
19.3.3. On the Basis of Patient Segment
19.4. Reimbursement Considerations for Antibody Drug Conjugates

20. CASE STUDY: CONTRACT MANUFACTURING OF ADCs 
20.1. Chapter Overview
20.2. Key Steps for ADC Manufacturing
20.3. Technical Challenges Associated with ADC Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitations of In-House Manufacturing
20.6. Investments in ADC Manufacturing Capability Expansions
20.7. Collaborations Established for ADC Manufacturing
20.8. Growing Demand for ADC Contract Manufacturing
20.9. Emergence of Start-Ups Offering Contract Services
20.10. CMOs with Linker Manufacturing Capabilities
20.11. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.12. CMOs with Conjugation Capabilities
20.13. ADC One-stop-shops

21. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS
21.1. Chapter Overview
21.1.1. Advantages of Companion Diagnostics
21.1.2. Challenges Associated with the Development of Companion Diagnostics

21.2. Companion Diagnostics for ADC Therapeutics
21.3. Other Companion Diagnostics
21.3.1. Analysis by Type of Target Antigen
21.3.2. Analysis by Type of Cancer
21.4. Most Active Players: Analysis by Number of Companion Diagnostics Developed

22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats

23. MARKET FORECAST AND OPPORTUNITY ANALYSIS
23.1. Chapter Overview
23.2. Scope and Limitations
23.3. Forecast Methodology

23.4. Overall Antibody Drug Conjugates Market
23.4.1. Antibody Drug Conjugates Market: Distribution by Target Disease Indication
23.4.2. Antibody Drug Conjugates Market: Distribution by Type of Linker
23.4.3. Antibody Drug Conjugates Market: Distribution by Type of Payload
23.4.4. Antibody Drug Conjugates Market: Distribution by Target Antigen
23.4.5. Antibody Drug Conjugates Market: Distribution by Geography

23.5. Antibody Drug Conjugates Market: Individual Drug Sales Forecasts
23.5.1. Adcetris
23.5.1.1. Target Patient Population
23.5.1.2. Sales Forecast

23.5.2. Kadcyla
23.5.2.1. Target Patient Population
23.5.2.2. Sales Forecast

23.5.3. Mylotarg
23.5.3.1. Target Patient Population
23.5.3.2. Sales Forecast

23.5.4. Besponsa
23.5.4.1. Target Patient Population
23.5.4.2. Sales Forecast

23.5.5. Lumoxiti
23.5.5.1. Target Patient Population
23.5.5.2. Sales Forecast

23.5.6. Polivy
23.5.6.1. Target Patient Population
23.5.6.2. Sales Forecast

23.5.7. Trodelvy
23.5.7.1. Target Patient Population
23.5.7.2. Sales Forecast

23.5.8. Enhertu
23.5.8.1. Target Patient Population
23.5.8.2. Sales Forecast

23.5.9. Zynlonta
23.5.9.1. Target Patient Population
23.5.9.2. Sales Forecast

23.5.10. Blenrep
23.5.10.1. Target Patient Population
23.5.10.2. Sales Forecast

23.5.11. Padcev
23.5.11.1. Target Patient Population
23.5.11.2. Sales Forecast

23.5.12. Tisotumab vedotin
23.5.12.1. Target Patient Population
23.5.12.2. Sales Forecast

23.5.13. Mirvetuximab soravtansine
23.5.13.1. Target Patient Population
23.5.13.2. Sales Forecast

23.5.14. ABBV-3373
23.5.14.1. Target Patient Population
23.5.14.2. Sales Forecast

23.5.15. Anetumab ravtansine
23.5.15.1. Target Patient Population
23.5.15.2. Sales Forecast

23.5.16. Disitamab vedotin
23.5.16.1. Target Patient Population
23.5.16.2. Sales Forecast

23.5.17. MRG002
23.5.17.1. Target Patient Population
23.5.17.2. Sales Forecast

23.5.18. Naratuximab emtansine
23.5.18.1. Target Patient Population
23.5.18.2. Sales Forecast

23.5.19. Trastuzumab duocarmazine
23.5.19.1. Target Patient Population
23.5.19.2. Sales Forecast

23.5.20. Tusamitamab ravtansine
23.5.20.1. Target Patient Population
23.5.20.2. Sales Forecast

23.5.21. Cetuximab sarotalocan
23.5.21.1. Target Patient Population
23.5.21.2. Sales Forecast

23.5.22. BA3011
23.5.22.1. Target Patient Population
23.5.22.2. Sales Forecast

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Oxford Biotherapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer

24.3. Angiex
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Executive Officer

24.4. Syndivia
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer

24.5. BSP Pharmaceuticals
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager

24.6. Abzena
24.6.1. Company Snapshot
24.6.2. Interview Transcript: John Burt, Chief Executive Officer

24.7. CureMeta
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Michael Schopperle, Chief Executive Officer

24.8. CytomX
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy

24.9. NBE-Therapeutics
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer

24.10. Cerbios-Pharma
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer

24.11. Eisai
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer

24.12. AbTis
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Justin Oh, Executive Director

24.13. AmbrX
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Sukumar Sakamuri, Vice President and Head of Chemistry

24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Director, Business Development

24.15. Pierre Fabre
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Christian Bailly, Director of CDMO

24.16. Catalent Pharma Solutions
24.16.1. Company Snapshot
24.16.2. Interview Transcript: Jennifer L. Mitcham, Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Group Product Manager

24.17. Lonza
24.17.1. Company Snapshot
24.17.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development

24.18. Piramal Healthcare
24.18.1. Company Snapshot
24.18.2. Interview Transcript: Mark Wright, Site Head

24.19. Ajinomoto Bio-Pharma Services
24.19.1. Company Snapshot
24.19.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager

24.20. Cardiff University
24.20.1. Company Snapshot
24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine

24.21. Anonymous, Chief Executive Officer, a Leading CMO
24.22. Anonymous, Director, Business Development, Leading CMO

25. CONCLUSION

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Historical Timeline of Cancer Therapies
Figure 3.2 Cancer Treatment: Type of Surgeries
Figure 3.3 Cancer Treatment: Type of Radiation Therapies
Figure 3.4 Cancer Treatment: Type of Chemotherapies
Figure 3.5 Components of an ADC
Figure 3.6 Comparative Study of Pharmacokinetic Properties of ADCs: Dosing Regimen, Cmax and T1/2
Figure 4.1 Antibody Drug Conjugates: Distribution by Phase of Development
Figure 4.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 4.3 Antibody Drug Conjugates: Key Solid Tumor Indications
Figure 4.4 Antibody Drug Conjugates: Key Hematological Malignancies
Figure 4.5 Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 4.6 Antibody Drug Conjugates: Distribution by Dosing Regimen
Figure 4.7 Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 4.8 Antibody Drug Conjugates: Distribution by Target Antigen
Figure 4.9 Antibody Drug Conjugates: Distribution by Antibody Origin
Figure 4.10 Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 4.11 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 4.12 Antibody Drug Conjugates: Distribution by Type of Payload / Warhead
Figure 4.13 Antibody Drug Conjugates: Distribution by Target Antigens and Target Disease Indications
Figure 4.14 Antibody Drug Conjugates: Grid Analysis
Figure 4.15 Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Figure 4.16 Antibody Drug Conjugate Developers: Distribution by Company Size
Figure 4.17 Antibody Drug Conjugate Developers: Distribution by Location of Headquarters
Figure 4.18 Most Active Players: Distribution by Number of Therapies
Figure 4.19 Logo Landscape: Distribution by Target Disease Indication and Company Size
Figure 5.1 Seagen: Annual Revenues, 2016 – Q1 2021 (USD Million)
Figure 5.2 Roche / Genentech: Annual Revenues, 2016 – 2020 (CHF Million)
Figure 5.3 Pfizer: Annual Revenues, 2016 – Q1 2021 (USD Billion)
Figure 5.4 AstraZeneca: Annual Revenues, 2016 – Q1 2021 (USD Million)
Figure 5.5 Astellas Pharma: Annual Revenues, 2016 – 2020 (JPY Million)
Figure 5.6 ImmunoGen: Annual Revenues, 2016 – Q1 2021 (USD Million)
Figure 5.7 Daiichi Sankyo: Annual Revenues, 2016 – 2020 (JPY Million)
Figure 5.8 Gilead: Annual Revenues, 2016 – 2020 (USD Million)
Figure 5.9 AbbVie: Annual Revenues, 2016 – 2020 (USD Billion)
Figure 5.10 Bayer: Annual Revenues, 2016 – 2020 (EUR Million)
Figure 6.1 Leukemia: Disease Classification
Figure 6.2 Leukemia: Global Epidemiological Distribution
Figure 6.3 Lymphoma: Global Epidemiological Distribution
Figure 6.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 6.5 Lung Cancer: Disease Classification
Figure 6.6 Lung Cancer: Global Epidemiological Distribution
Figure 6.7 Breast Cancer: Global Epidemiological Distribution
Figure 6.8 Ovarian Cancer: Global Epidemiological Distribution
Figure 6.9 Bladder Cancer: Global Epidemiological Distribution
Figure 6.10 Colorectal Cancer: Global Epidemiological Distribution
Figure 6.11 Prostate Cancer: Global Epidemiological Distribution
Figure 6.12 Gastric Cancer: Global Epidemiological Distribution
Figure 7.1 Adcetris: Geographical Distribution of Principle Investigators
Figure 7.2 Kadcyla: Geographical Distribution of Principle Investigators
Figure 7.3 Mylotarg: Geographical Distribution of Principle Investigators
Figure 7.4 Other ADCs: Geographical Distribution of Principle Investigators
Figure 7.5 KOL Analysis: Dot-Plot of Principal Investigators
Figure 7.6 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 7.7 KOL Analysis: Most Prominent KOLs
Figure 8.1 Antibody Drug Conjugates: Four-Dimensional Bubble Analysis
Figure 8.2 Antibody Drug Conjugates: Five-Dimensional Spider-Web Analysis
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014-2021
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Cumulative Trend by Year and Type of Partnership, 2014-2021
Figure 9.4 Most Active Players: Distribution by Number of Partnerships
Figure 9.5 Partnerships and Collaborations: Regional Distribution
Figure 9.6 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investment Analysis: Cumulative Number of Funding Instances by Year, 2014-2021
Figure 10.2 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2014-2021 (USD Million)
Figure 10.3 Funding and Investment Analysis: High Value Deals, 2014-2021 (USD Million)
Figure 10.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2021
Figure 10.5 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2014-2021 (USD Million)
Figure 10.6 Most Active Players: Distribution by Number of Funding Instances
Figure 10.7 Most Active Players: Distribution by Amount Invested
Figure 10.8 Most Active Investors: Distribution by Number of Funding Instances
Figure 10.9 Funding and Investment Summary, 2014-2021 (USD Million)
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year, 2001-2021
Figure 11.3 Patent Analysis: Distribution by Geography
Figure 11.4 Patent Analysis: Distribution by CPC Symbols
Figure 11.5 Patent Analysis: Emerging Focus Areas
Figure 11.6 Patent Analysis: Distribution by Type of Organization
Figure 11.7 Leading Industry Players: Distribution by Number of Patents
Figure 11.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.9 Patent Analysis: Benchmarking by Patent Characteristics
Figure 11.10 Patent Analysis: Benchmarking by Number of International Patents
Figure 11.11 Patent Analysis: Distribution by Patents Age (2001-2021)
Figure 11.12 Patent Analysis: Distribution of Patents by Geography (2001-2021)
Figure 11.13 Patent Analysis: Valuation Analysis
Figure 12.1 Grant Analysis: Cumulative Year-Wise Trend of Grants Awarded, 2016-2021
Figure 12.2 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2021
Figure 12.3 Grant Analysis: Distribution by Administering Institute Center
Figure 12.4 Grant Analysis: Distribution by Support Period
Figure 12.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 12.6 Grant Analysis: Distribution by Type of Grant Application
Figure 12.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 12.8 Grant Analysis: Distribution by Activity Code
Figure 12.9 Word Cloud: Emerging Focus Areas
Figure 12.10 Grant Analysis: Distribution by Study Section Involved
Figure 12.11 Popular NIH Departments: Distribution by Number of Grants
Figure 12.12 Grant Analysis: Distribution by Type of Recipient Organization
Figure 12.13 Most Prominent Program Officers: Distribution by Number of Grants
Figure 12.14 Popular Recipient Organizations: Distribution by Number of Grants
Figure 12.15 Regional Distribution of Recipient Organizations
Figure 13.1 Clinical Trial Analysis: Scope and Methodology
Figure 13.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 13.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2016-2021
Figure 13.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 13.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status, 2016-2021
Figure 13.6 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2016-2021
Figure 13.7 Clinical Trial Analysis: Distribution by Study Design
Figure 13.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 13.9 Most Active Players: Distribution by Number of Registered Trials
Figure 13.10 Clinical Trial Analysis: Emerging Focus Areas
Figure 13.11 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 13.12 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 14.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 14.2 Successful Drug Launch Strategy: Product Differentiation
Figure 14.3 Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 14.4 Harvey Ball Analysis: Key Commercialization Strategies Adopted by Companies Developing ADCs
Figure 14.5 Approval of Drugs in Multiple Geographies: Historical Timeline
Figure 14.6 Approved ADC Therapeutics: Snapshot of Promotional Activities on Product Websites
Figure 15.1 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.2 Promotional / Marketing Strategy: Patient Brochure and Unique Features
Figure 15.3 Promotional / Marketing Strategy: Informative Downloads
Figure 15.4 Adcetris Website Analysis: Messages for Healthcare Professionals
Figure 15.5 Adcetris Website Analysis: Messages for Patients
Figure 15.6 Adcetris Website Analysis: Patient Support Services
Figure 15.7 Kadcyla Website Analysis: Messages for Healthcare Professionals
Figure 15.8 Kadcyla Website Analysis: Messages for Patients
Figure 15.9 Kadcyla Website Analysis: Patient Support Services
Figure 15.10 Mylotarg Website Analysis: Messages for Healthcare Professionals
Figure 15.11 Mylotarg Website Analysis: Messages for Patients
Figure 15.12 Mylotarg Website Analysis: Patient Support Services
Figure 15.13 Mylotarg Website Analysis: Pfizer Oncology Together Program
Figure 15.14 Besponsa Website Analysis: Messages for Healthcare Professionals
Figure 15.15 Besponsa Website Analysis: Messages for Patients
Figure 15.16 Besponsa Website Analysis: Patient Support Services
Figure 15.17 Besponsa Website Analysis: Pfizer Oncology Together Program
Figure 15.18 Lumoxiti Website Analysis: Messages for Healthcare Professionals
Figure 15.19 Lumoxiti Website Analysis: Messages for Patients
Figure 15.20 Lumoxiti Website Analysis: Patient Support Services
Figure 15.21 Polivy Website Analysis: Messages for Healthcare Professionals
Figure 15.22 Polivy Website Analysis: Messages for Patients
Figure 15.23 Polivy Website Analysis: Patient Support Services
Figure 16.1 Antibody Drug Conjugates: Distribution by Type of Therapy Evaluation
Figure 16.2 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Figure 16.3 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Current Trial Status
Figure 16.4 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination Therapy
Figure 16.5 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Target Disease Indication and Type of Combination Therapy
Figure 17.1 ADC Platforms: Technological Evolution
Figure 17.2 ADC Conjugation Platforms: Technology Landscape
Figure 18.1 First in Human Dose Calculation: Dose Escalation using BSA Conversion
Figure 18.2 Relationship between Dose-Limiting Toxicities and ADC Warhead
Figure 18.3 Maximum Tolerated Dose (MTD): Relationship between Drug to Antibody Ratio and Highest Non-Severely Toxic Dose (HNSTD)
Figure 19.1 Antibody Drug Conjugates: Relative Share of Individual Processes in the Cost of Production
Figure 19.2 Antibody Drug Conjugates: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (Without Licensing Fee)
Figure 19.3 Antibody Drug Conjugates: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (With Licensing Fee)
Figure 19.4 Antibody Drug Conjugates: Pricing Model Based on Patient Segment
Figure 19.5 Antibody Drug Conjugates: Pricing Model Based on Reimbursement Approvals
Figure 20.1 ADC Contract Manufacturers: Distribution by Services Offered
Figure 21.1 Advantages of Companion Diagnostics
Figure 21.2 Companion Diagnostics Applicable to Antibody Drug Conjugates: Distribution by Target Antigen
Figure 21.3 Companion Diagnostics Applicable to Antibody Drug Conjugates: Distribution by Type of Cancer
Figure 21.4 Companion Diagnostics Applicable to Antibody Drug Conjugates: Key Players
Figure 22.1 Antibody Drug Conjugates: SWOT Analysis
Figure 22.2 Antibody Drug Conjugates SWOT Analysis: Strengths
Figure 22.3 Antibody Drug Conjugates SWOT Analysis: Weaknesses
Figure 22.4 Antibody Drug Conjugates SWOT Analysis: Opportunities
Figure 22.5 Antibody Drug Conjugates SWOT Analysis: Threats
Figure 23.1 Overall Antibody Drug Conjugates Market, 2021-2030 (USD Billion)
Figure 23.2 Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2021, 2025 and 2030 (USD Billion)
Figure 23.3 Antibody Drug Conjugates Market: Distribution by Type of Linker, 2021, 2025 and 2030 (USD Billion)
Figure 23.4 Antibody Drug Conjugates Market: Distribution by Type of Payload, 2021, 2025 and 2030 (USD Billion)
Figure 23.5 Antibody Drug Conjugates Market: Distribution by Type of Target Antigen, 2021, 2025 and 2030 (USD Billion)
Figure 23.6 ADC Therapeutics Market: Distribution by Geography, 2021, 2025 and 2030 (USD Billion)
Figure 23.7 Adcetris: Target Patient Population
Figure 23.8 Adcetris Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.9 Kadcyla: Target Patient Population
Figure 23.10 Kadcyla Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.11 Mylotarg: Target Patient Population
Figure 23.12 Mylotarg Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.13 Besponsa: Target Patient Population
Figure 23.14 Besponsa Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.15 Lumoxiti: Target Patient Population
Figure 23.16 Lumoxiti Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.17 Polivy: Target Patient Population
Figure 23.18 Polivy Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.19 Trodelvy: Target Patient Population
Figure 23.20 Trodelvy Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.21 Enhertu: Target Patient Population
Figure 23.22 Enhertu Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.23 Zynlonta: Target Patient Population
Figure 23.24 Zynlonta Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.25 Blenrep: Target Patient Population
Figure 23.26 Blenrep Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.27 Padcev: Target Patient Population
Figure 23.28 Padcev Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.29 Tisotumab Vedotin: Target Patient Population
Figure 23.30 Tisotumab Vedotin Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.31 Mirvetuximab Soravtansine: Target Patient Population
Figure 23.32 Mirvetuximab Soravtansine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.33 ABBV-3373: Target Patient Population
Figure 23.34 ABBV-3373 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.35 Anetumab Ravtansine: Target Patient Population
Figure 23.36 Anetumab Ravtansine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.37 Disitamab Vedotin: Target Patient Population
Figure 23.38 Disitamab Vedotin Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.39 MRG002: Target Patient Population
Figure 23.40 MRG002 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.41 Naratuximab Emtansine: Target Patient Population
Figure 23.42 Naratuximab Emtansine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.43 Trastuzumab Duocarmazine: Target Patient Population
Figure 23.44 Trastuzumab Duocarmazine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.45 Tusamitamab Ravtansine: Target Patient Population
Figure 23.46 Tusamitamab Ravtansine Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.47 Cetuximab Sarotalocan: Target Patient Population
Figure 23.48 Cetuximab Sarotalocan Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 23.49 BA3011: Target Patient Population
Figure 23.50 BA3011 Sales Forecast (Till 2030): Base Scenario (USD Million)

List Of Tables

Table 3.1 List of Approved Monoclonal Antibody Therapies
Table 3.2 Commonly Used Cytotoxins for Antibody Drug Conjugates
Table 3.3 Occupational Exposure Limit Bands, SafeBridge Consultants
Table 3.4 Comparison of Pharmacokinetic Properties: ADCs, Small Molecules and Monoclonal Antibodies
Table 4.1 Antibody Drug Conjugates: Drug Pipeline
Table 4.2 Antibody Drug Conjugates: Component Specific Details
Table 4.3 Antibody Drug Conjugates: Distribution by Target Antigen and Target Disease Indication(s)
Table 4.4 Antibody Drug Conjugates: List of Developers
Table 4.5 Antibody Drug Conjugates: Technology Platforms
Table 4.6 Novel Drug Conjugates
Table 4.7 Antibody Drug Conjugates: Discontinued Drugs
Table 5.1 Seagen: Company Overview
Table 5.2 Seagen: Antibody Drug Conjugates Pipeline
Table 5.3 Drug Profile: Adcetris
Table 5.4 Drug Profile: Padcev
Table 5.5 Drug Profile: HuMax-TF
Table 5.6 Drug Profile: SGN-LIV1A
Table 5.7 Seagen: Recent Developments and Future Outlook
Table 5.8 Roche / Genentech: Company Overview
Table 5.9 Roche / Genentech: Antibody Drug Conjugates Pipeline
Table 5.10 Drug Profile: Kadcyla
Table 5.11 Drug Profile: Polivy
Table 5.12 Roche / Genentech: Recent Developments and Future Outlook
Table 5.13 Pfizer: Company Overview
Table 5.14 Pfizer: Antibody Drug Conjugates Pipeline
Table 5.15 Drug Profile: Mylotarg
Table 5.16 Drug Profile: Besponsa
Table 5.17 Pfizer: Recent Developments and Future Outlook
Table 5.18 AstraZeneca: Company Overview
Table 5.19 AstraZeneca: Antibody Drug Conjugates Pipeline
Table 5.20 Drug Profile: Enhertu
Table 5.21 AstraZeneca: Recent Developments and Future Outlook
Table 5.22 Astellas Pharma: Company Overview
Table 5.23 Astellas Pharma: Antibody Drug Conjugates Pipeline
Table 5.24 Astellas Pharma: Recent Developments and Future Outlook
Table 5.25 ImmunoGen: Company Overview
Table 5.26 ImmunoGen: Antibody Drug Conjugates Pipeline
Table 5.27 Drug Profile: Mirvetuximab soravtansine
Table 5.28 ImmunoGen: Recent Developments and Future Outlook
Table 5.29 Daiichi Sankyo: Company Overview
Table 5.30 Daiichi Sankyo: Antibody Drug Conjugates Pipeline
Table 5.31 Drug Profile: Patritumab deruxtecan
Table 5.32 Drug Profile: Datopotamab deruxtecan
Table 5.33 Daiichi Sankyo: Recent Developments and Future Outlook
Table 5.34 Gilead: Company Overview
Table 5.35 Gilead: Antibody Drug Conjugates Pipeline
Table 5.36 Drug Profile: Trodelvy
Table 5.37 Gilead: Recent Developments and Future Outlook
Table 5.38 AbbVie: Company Overview
Table 5.39 AbbVie: Antibody Drug Conjugates Pipeline
Table 5.40 Drug Profile: Telisotuzumab vedotin
Table 5.41 Drug Profile: ABBV-3373
Table 5.42 AbbVie: Recent Developments and Future Outlook
Table 5.43 Bayer: Company Overview
Table 5.44 Bayer: Antibody Drug Conjugates Pipeline
Table 5.45 Drug Profile: Anetumab ravtansine
Table 5.46 Bayer: Recent Developments and Future Outlook
Table 5.47 RemeGen: Company Overview
Table 5.48 RemeGen: Antibody Drug Conjugates Pipeline
Table 5.49 Drug Profile: Disitamab vedotin
Table 5.50 RemeGen: Recent Developments and Future Outlook
Table 5.51 ADC Therapeutics: Company Overview
Table 5.52 ADC Therapeutics: Antibody Drug Conjugates Pipeline
Table 5.53 Drug Profile: Zynlonta
Table 5.54 Drug Profile: Camidanlumab tesirine
Table 5.55 ADC Therapeutics: Recent Developments and Future Outlook
Table 6.1 Comparison between Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 6.2 Leukemia: List of Marketed Targeted Therapeutics
Table 6.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 6.4 ADC Therapeutics for Leukemia and Lymphoma
Table 6.5 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 6.6 ADC Therapeutics for Multiple Myeloma
Table 6.7 Lung Cancer: List of Marketed Targeted Therapeutics
Table 6.8 ADC Therapeutics for Lung Cancer
Table 6.9 Breast Cancer: List of Marketed Targeted Therapeutics
Table 6.10 ADC Therapeutics for Breast Cancer
Table 6.11 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 6.12 ADC Therapeutics for Ovarian Cancer
Table 6.13 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 6.14 ADC Therapeutics for Bladder Cancer
Table 6.15 Colorectal Cancer: List of Marketed Targeted Therapeutics
Table 6.16 ADC Therapeutics for Colorectal Cancer
Table 6.17 Prostate Cancer: List of Marketed Targeted Therapeutics
Table 6.18 ADC Therapeutics for Prostate Cancer
Table 6.19 Gastric Cancer: List of Marketed Targeted Therapeutics
Table 6.20 ADC Therapeutics for Gastric Cancer
Table 7.1 KOLs: List of Principal Investigators
Table 7.2 KOLs: List of Universities and Hospitals
Table 7.3 KOLs: Roots Analysis Proprietary Scoring System
Table 7.4 KOL Profile: KOL A (Celgene)
Table 7.5 KOL Profile: KOL B (Georgetown University Medical Center)
Table 7.6 KOL Profile: KOL C (Cancer Hospital and Institute)
Table 7.7 KOL Profile: KOL D (Comprehensive Cancer Centers of Nevada)
Table 9.1 Antibody Drug Conjugates: List of Partnerships and Collaborations, 2014-2021
Table 10.1 Antibody Drug Conjugates: List of Funding and Investments, 2014-2021
Table 10.2 Funding and Investments: Average Amount Invested by Year, 2014-2021 (USD Million)
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: List of Top CPC Symbols
Table 11.3 Patent Portfolio: Summary of Benchmarking Analysis
Table 11.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.5 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 12.1 Antibody Drug Conjugates: List of Academic Grants, 2016-2021
Table 14.1 Adcetris: Drug Overview
Table 14.2 Kadcyla: Drug Overview
Table 14.3 Mylotarg: Drug Overview
Table 14.4 Besponsa: Drug Overview
Table 14.5 Lumoxiti: Drug Overview
Table 14.6 Polivy: Drug Overview
Table 14.7 Adcetris: Participation in Conferences Before Product Approval
Table 14.8 Mylotarg: Participation in Conferences Before Product Approval
Table 14.9 Kadcyla: Participation in Conferences Before Product Approval
Table 14.10 Besponsa: Participation in Conferences Before Product Approval
Table 14.11 Lumoxiti: Participation in Conferences Before Product Approval
Table 14.12 Polivy: Participation in Conferences Before Product Approval
Table 14.13 Adcetris: Participation in Conferences Post Product Approval
Table 14.14 Kadcyla: Participation in Conferences Post Product Approval
Table 14.15 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 16.1 Antibody Drug Conjugates Combination Therapy Clinical Studies: Key Indications
Table 17.1 Second-Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 17.2 Second-Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 17.3 Second-Generation ADC Technologies: Amino-terminal Engineered Serine
Table 17.4 Third-Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 17.5 Third-Generation ADC Technologies: Glycan Remodeling Approaches
Table 17.6 Third-Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 17.7 Third-Generation ADC Technologies: Cysteine Rebridging
Table 17.8 Third-Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 18.1 ADC Therapeutics Non-Clinical Studies: Safety Packages Required
Table 18.2 Single Dose Study of Kadcyla in Cynomolgus Monkey
Table 18.3 ADC Therapeutics: Dose Limiting Toxicities in Clinical Studies
Table 19.1 ADC Components: Information on Cost by Type of Linker
Table 19.2 ADC Components: Information on Cost by Type of Cytotoxin
Table 19.3 Price of Marketed ADCs
Table 19.4 Price of Other Marketed Targeted Therapies
Table 20.1 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 20.2 List of HPAPI and Cytotoxic Drugs Manufacturing Service Providers
Table 20.3 Contract Manufacturers for ADC Therapeutics: Geographical Distribution
Table 20.4 One Stop Shops for ADC Manufacturing: Information on Location of Manufacturing Facilities
Table 21.1 Companion Diagnostics: List of Available / Under Development Tests for ADCs
Table 21.2 Companion Diagnostics: List of Available / Under Development Tests for Clinical ADCs
Table 21.3 Companion Diagnostics: Partnerships and Collaborations, 2014-2019
Table 21.4 Companion Diagnostics Applicable to ADC Therapeutics: List of Available / Under Development Tests
Table 23.1 ADC Therapeutics: Information on Expected Launch Year
Table 24.1 Oxford Biotherapeutics: Company Snapshot
Table 24.2 Angiex: Company Snapshot
Table 24.3 Syndivia: Company Snapshot
Table 24.4 BSP Pharmaceuticals: Company Snapshot
Table 24.5 Abzena: Company Snapshot
Table 24.6 CureMeta: Company Snapshot
Table 24.7 CytomX: Company Snapshot
Table 24.8 NBE-Therapeutics: Company Snapshot
Table 24.9 Cerbios-Pharma: Company Snapshot
Table 24.10 Eisai: Company Snapshot
Table 24.11 AbTis: Company Snapshot
Table 24.12 AmbrX: Company Snapshot
Table 24.13 Synaffix: Company Snapshot
Table 24.14 Pierre Fabre: Company Snapshot
Table 24.15 Catalent Pharma Solutions: Company Snapshot
Table 24.16 Lonza: Company Snapshot
Table 24.17 Piramal Healthcare: Company Snapshot
Table 24.18 Ajinomoto Bio-Pharma Services: Company Snapshot
Table 24.19 Cardiff University: Company Snapshot
Table 26.1 Antibody Drug Conjugates: Distribution by Phase of Development
Table 26.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 26.3 Antibody Drug Conjugates: Key Solid Tumor Indications
Table 26.4 Antibody Drug Conjugates: Key Hematological Malignancies
Table 26.5 Antibody Drug Conjugates: Distribution by Line of Treatment
Table 26.6 Antibody Drug Conjugates: Distribution by Dosing Regimen
Table 26.7 Antibody Drug Conjugates: Distribution by Type of Therapy
Table 26.8 Antibody Drug Conjugates: Distribution by Target Antigen
Table 26.9 Antibody Drug Conjugates: Distribution by Antibody Origin
Table 26.10 Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 26.11 Antibody Drug Conjugates: Distribution by Type of Linker
Table 26.12 Antibody Drug Conjugates: Distribution by Type of Payload / Warhead
Table 26.13 Antibody Drug Conjugates: Distribution by Target Antigens and Target Disease Indications
Table 26.14 Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Table 26.15 Antibody Drug Conjugate Developers: Distribution by Company Size
Table 26.16 Antibody Drug Conjugate Developers: Distribution by Location of Headquarters
Table 26.17 Most Active Players: Distribution by Number of Therapies
Table 26.18 Seagen: Annual Revenues, 2016 – Q1 2021 (USD Million)
Table 26.19 Roche / Genentech: Annual Revenues, 2016 – 2020 (CHF Million)
Table 26.20 Pfizer: Annual Revenues, 2016 – Q1 2021 (USD Billion)
Table 26.21 AstraZeneca: Annual Revenues, 2016 – Q1 2021 (USD Million)
Table 26.22 Astellas Pharma: Annual Revenues, 2016 – 2020 (JPY Million)
Table 26.23 ImmunoGen: Annual Revenues, 2016 – Q1 2021 (USD Million)
Table 26.24 Daiichi Sankyo: Annual Revenues, 2016 – 2020 (JPY Million)
Table 26.25 Gilead: Annual Revenues, 2016 – 2020 (USD Million)
Table 26.26 AbbVie: Annual Revenues, 2016 – 2020 (USD Billion)
Table 26.27 Bayer: Annual Revenues, 2016 – 2020 (EUR Million)
Table 26.28 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Table 26.29 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014-2021
Table 26.30 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.31 Partnerships and Collaborations: Cumulative Trend by Year and Type of Partnership, 2014-2021
Table 26.32 Most Active Players: Distribution by Number of Partnerships
Table 26.33 Partnerships and Collaborations: Regional Distribution
Table 26.34 Funding and Investment Analysis: Cumulative Number of Finding Instances by Year, 2014-2021
Table 26.35 Funding and Investment Analysis: Cumulative Amount Invested by Year, 2014-2021 (USD Million)
Table 26.36 Funding and Investment Analysis: High Value Deals, 2014-2021 (USD Millions)
Table 26.37 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2021
Table 26.38 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2014-2021 (USD Million)
Table 26.39 Most Active Players: Distribution by Number of Funding Instances
Table 26.40 Most Active Players: Distribution by Amount Invested
Table 26.41 Most Active Investors: Distribution by Number of Funding Instances
Table 26.42 Patent Analysis: Distribution by Type of Patent
Table 26.43 Patent Analysis: Cumulative Distribution by Publication Year, 2001-2021
Table 26.44 Patent Analysis: Distribution by Geography
Table 26.45 Patent Analysis: Distribution by Type of Organization
Table 26.46 Leading Industry Players: Distribution by Number of Patents
Table 26.47 Leading Non-Industry Players: Distribution by Number of Patents
Table 26.48 Patent Analysis: Distribution by Patents Age (2001-2021)
Table 26.49 Patent Analysis: Distribution of Patents by Geography (2001-2021)
Table 26.50 Patent Analysis: Valuation Analysis
Table 26.51 Grant Analysis: Cumulative Year-Wise Trend of Grants Awarded, 2016-2021
Table 26.52 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2021
Table 26.53 Grant Analysis: Distribution by Administering Institute Center
Table 26.54 Grant Analysis: Distribution by Support Period
Table 26.55 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 26.56 Grant Analysis: Distribution by Type of Grant Application
Table 26.57 Grant Analysis: Distribution by Purpose of Grant Award
Table 26.58 Grant Analysis: Distribution by Activity Code
Table 26.59 Grant Analysis: Distribution by Study Section Involved
Table 26.60 Popular NIH Departments: Distribution by Number of Grants
Table 26.61 Grant Analysis: Distribution by Type of Recipient Organization
Table 26.62 Most Prominent Program Officers: Distribution by Number of Grants
Table 26.63 Popular Recipient Organization: Distribution by Number of Grants
Table 26.64 Clinical Trial Analysis: Distribution by Trial Status
Table 26.65 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2016-2021
Table 26.66 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.67 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status, 2016-2021
Table 26.68 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2016-2021
Table 26.69 Clinical Trial Analysis: Distribution by Study Design
Table 26.70 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.71 Most Active Players: Distribution by Number of Registered Trials
Table 26.72 Antibody Drug Conjugates: Distribution by Type of Therapy Evaluation
Table 26.73 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Table 26.74 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Current Trial Status
Table 26.75 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination Therapy
Table 26.76 Antibody Drug Conjugates Combination Therapy Clinical Studies: Distribution by Target Disease Indications and Type of Combination Therapy
Table 26.77 Antibody Drug Conjugates: Relative Share of Individual Processes in the Cost of Production
Table 26.78 Antibody Drug Conjugates: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (Without Licensing Fees)
Table 26.79 Antibody Drug Conjugates: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (With Licensing Fees)
Table 26.80 ADC Contract Manufacturers: Distribution by Services Offered
Table 26.81 Companion Diagnostics Applicable to Antibody Drug Conjugates: Distribution by Target Antigen
Table 26.82 Companion Diagnostics Applicable to Antibody Drug Conjugates: Distribution by Type of Cancer
Table 26.83 Companion Diagnostics Applicable to Antibody Drug Conjugates: Key Players
Table 26.84 Overall Antibody Drug Conjugates Market, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 26.85 Antibody Drug Conjugates Market: Distribution by Target Disease Indication, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.86 Antibody Drug Conjugates Market: Distribution by Type of Linker, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.87 Antibody Drug Conjugates Market: Distribution by Type of Payload, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.88 Antibody Drug Conjugates Market: Distribution by Type of Target Antigen, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.89 ADC Therapeutics Market: Distribution by Geography, Conservative, Base, and Optimistic Scenarios, 2021, 2025 and 2030 (USD Billion)
Table 26.90 Adcetris Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.91 Kadcyla Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.92 Mylotarg Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.93 Besponsa Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.94 Lumoxiti Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.95 Polivy Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.96 Trodelvy Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.97 Enhertu Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.98 Zynlonta Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.99 Blenrep Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.100 Padcev Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.101 Tisotumab Vedotin Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.102 Mirvetuximab Soravtansine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.103 ABBV-3373 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.104 Anetumab Ravtansine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.105 Disitamab Vedotin Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.106 MRG002 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.107 Naratuximab Emtansine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.108 Trastuzumab Duocarmazine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.109 Tusamitamab Ravtansine Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.110 Cetuximab Sarotalocan Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)
Table 26.111 BA3011 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 3SBio
2. 3W Partners
3. 4BIO Capital
4. 5AM Ventures
5. 6 Dimensions Capital
6. AbbVie
7. ABL Bio
8. AbTis
9. Actinium Pharmaceuticals (ATNM)
10. Acuta Capital Partners
11. Adage Capital Management
12. Adagene
13. ADC Therapeutics
14. Adcendo
15. Advanced Proteome Therapeutics
16. Advantech
17. Agensys
18. Ajinomoto Bio-Pharma
19. Ally Bridge Group
20. Alphamab Oncology
21. Alta Partners
22. Alteogen
23. AltruBio
24. Ambrx
25. Amgen
26. Amgen Ventures
27. Angiex
28. Antikor Biopharma
29. Apricot Capital
30. Aravis
31. ARCH Venture Partners
32. Arix Bioscience
33. Arrowpoint Partners
34. Asana BioSciences
35. Astellas Pharma
36. AstraZeneca
37. Auven Therapeutics
38. Avacta
39. Avalon Ventures
40. AVICT Global
41. Avipep Therapeutics
42. AVROBIO
43. Bayer
44. Bayern Kapital
45. BDC Capital
46. Beam Therapeutics
47. BeiGene
48. BioAtla
49. BioGeneration Ventures (BGV)
50. BioMed Valley Discoveries
51. BioMedPartners
52. Biotest
53. BlackRock
54. BlinkBio
55. Boehringer Ingelheim 
56. Boehringer Ingelheim Venture Fund
57. BOM Capital
58. Boxer Capital
59. Boyu Capital
60. Bregua
61. BrickBio
62. BrightGene Bio-Medical Technology
63. Bristol-Myers Squibb
64. btov Partners
65. BVF Partners
66. Byondis
67. Calculus Capital
68. California Institute for Regenerative Medicine (CIRM)
69. Cambridge Enterprise, University of Cambridge
70. Canaan Partners
71. Cancer Prevention and Research Institute of Texas (CPRIT)
72. Cancer Research Technology (CRT)
73. Cancer Research UK
74. Casdin Capital
75. Catalent
76. Catalent Biologics
77. CEL Healthcare
78. Celgene
79. Cellerant Therapeutics
80. Celltrion
81. Centre for the Commercialization of Antibodies and Biologics (CCAB)
82. Centrose
83. Changjinboya
84. Chengcheng Capital
85. Chiesi Ventures
86. Children’s Hospital Los Angeles
87. China Life Private Equity Investment
88. China Venture Capital Fund (CVC)
89. CITIC Private Equity (CPE) 
90. Clovis Oncology
91. Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator     (CARB-X)
92. Coparion
93. Cormorant Asset Management
94. Crescendo Biologics
95. CStone Pharmaceuticals
96. CTI Life Sciences Fund
97. CureMeta
98. CytomX Therapeutics
99. Daiichi Sankyo
100. Debiopharm
101. Decheng Capital
102. Deerfield Management
103. Diatheva
104. dievini Hopp BioTech
105. Efung Capital
106. EirGenix
107. Eli Lilly
108. EMD Serono
109. Esperance Pharmaceuticals
110. Essex Bio-Technology
111. Eurostars
112. Eventide
113. Everest Medicines
114. Exelixis
115. Farallon Capital
116. Femtogenix 
117. Fidelity Investments
118. Five Prime Therapeutics
119. Florida Institute of Technology
120. Fonds de solidarité FTQ
121. Foresite Capital
122. Fortis Therapeutics
123. Fosun Pharma (formerly Shanghai Fosun Pharmaceutical)
124. Freenome
125. GamaMabs Pharma
126. Genentech
127. GeneQuantum Healthcare
128. General Insurance Corporation of India (GIC)
129. Genmab
130. Genor Biopharma
131. GIC
132. Gilde Healthcare
133. Gilead Sciences
134. GlaxoSmithKline
135. Global Bio-India
136. Glycotope
137. Glykos
138. Glythera
139. Goodwin Biotechnology
140. Greater Bay Area Fund
141. GT Biopharma
142. Guotai Venture Capital
143. Gustave Roussy
144. Hangzhou DAC Biotech
145. Harbour BioMed
146. HBM Healthcare Investments
147. HealthCap
148. Heidelberg Pharma
149. Hercules Capital
150. Heritage Provider Network
151. High-Tech Gründerfonds
152. Hillhouse Capital
153. Hisun Pharmaceuticals
154. Hofon Capital
155. Sichuan Hongbo Equity Investment Fund Management
156. HOPU Investments
157. Huadong Medicine
158. Huagai Capital
159. Hudson Bay Capital Management
160. Humanwell Healthcare 
161. Iconic Therapeutics
162. Iksuda Therapeutics
163. ImmuneOncia Therapeutics
164. ImmunoBiochem
165. ImmunoGen
166. Immunome
167. Immunomedics (acquired by Gilead Sciences)
168. Innate Pharma
169. Innovate UK
170. Invenra
171. Invus
172. IONTAS
173. IP Group
174. iProgen Biotech
175. Janchor Partners
176. Janus Henderson Investors
177. Jazz Pharmaceuticals
178. Jiangsu Hengrui Pharmaceuticals
179. JLABS 
180. Johnson & Johnson Innovation
181. Johnson Matthey
182. JT New Century
183. JX Partners
184. K2 Investment
185. Kairos Therapeutics
186. King Star Capital
187. Kite Pharma
188. KLUS Pharma
189. Lake Bleu Capital
190. Laurion Capital Management
191. Legend Capital
192. LegoChem Biosciences
193. Levena Biopharma
194. LifeSci Venture Partners
195. Lilly Asia Ventures (LAV)
196. Lilly Ventures
197. Logos Capital
198. Loyal Valley Capital
199. Lumira Capital
200. MAB Discovery
201. MabSpace Biosciences
202. MabVax
203. MacroGenics
204. Magenta Therapeutics
205. Matrix Capital Management
206. Mayo Clinic
207. MediaPharma
208. MedImmune (acquired by AstraZeneca)
209. Meltwind
210. Memorial Sloan Kettering Cancer Center
211. Menarini
212. Merck
213. Merck KGaA
214. Mersana Therapeutics
215. Millennium Pharmaceuticals
216. MilliporeSigma
217. Minomic
218. Shanghai Miracogen
219. Mitsubishi Tanabe Pharma
220. Morphotek (Eisai)
221. MS Ventures
222. Multiple Myeloma Research Foundation (MMRF)
223. Myeloma Investment Fund
224. NanoValent Pharmaceuticals
225. National Cancer Institute (NCI)
226. National Research Council of Canada (NRC)
227. Navrogen
228. NBE-Therapeutics
229. Nerviano Medical Sciences
230. New Enterprise Associates
231. Nexthera Capital
232. Nordic Nanovector
233. Northeast Securities Prosperity Healthcare Fund
234. NovImmune
235. Novo Holdings
236. NovoCodex Biopharmaceuticals
237. o2h Ventures
238. OBI Pharma
239. OCCIDENT
240. OGD2 Pharma
241. Oncolinx
242. Oncomatryx Biopharma
243. OPKO Health
244. OrbiMed Advisors
245. Oriza Seed Venture Capital
246. Osage University Partners
247. Otsuka Pharmaceutical
248. Overland ADCT BioPharma
249. Oxford BioTherapeutics (OBT) 
250. Oxford Finance
251. PAG
252. Pappas Capital
253. Perceptive Advisors
254. Pfizer
255. Pfizer Ventures
256. pH Pharma
257. PharmAbcine
258. PharmaMar
259. Philogen
260. PICC Capital Equity Investment
261. Pierre Fabre
262. PolyTherics
263. PPF Capital Partners Fund
264. Puma Biotechnology
265. Pureos Bioventures
266. Pyxis
267. Pyxis Oncology
268. Qiming Venture Partners
269. Quantum Leap
270. RA Capital Management
271. Rakuten
272. Rakuten Medical
273. Ramot
274. Recepta Biopharma
275. Redalpine
276. Redmile Group
277. Redwood BioScience
278. Regeneron Pharmaceuticals
279. RemeGen
280. The Research Council of Norway
281. Ridgeback Capital Investments
282. Roche
283. Roche Venture Fund
284. Rock Springs Capital
285. RTW Investments
286. Samsara BioCapital
287. Samsung Biologics
288. Sanofi
289. Sarah Cannon Research Institute
290. SBI Group
291. Schroder Adveq (acquired by Schroders)
292. Seagen
293. Sequoia Capital China
294. Seventure Partners
295. Shanghai Pharmaceuticals
296. Shengda Group
297. Shenogen Pharma
298. Siamab Therapeutics
299. Silicon Valley Bank
300. Sinopharm Capital
301. SK
302. Skyline Ventures
303. Sofinnova Ventures
304. Soleus Capital
305. SOPHiA GENETICS
306. Sorrento Therapeutics
307. SOTIO
308. Springworks
309. Starling Ventures
310. Start Codon
311. Stonebridge Capital
312. Surveyor Capital
313. Sutro Biopharma
314. Suvretta Capital Management
315. Suzhou Wuzhong Biomedicine Industrial Park Investment
316. SV Health Investors
317. Synaffix
318. SyndicateRoom
319. Syndivia
320. Synthon
321. T. Rowe Price Associates
322. Taikang Insurance Group
323. Takeda Oncology
324. Takeda Pharmaceutical
325. Takeda Ventures
326. Tekla Capital Management
327. Terra Magnum Capital Partners (TMCP)
328. TF Capital
329. The Column Group
330. The Scripps Research Institute
331. Third Rock Ventures
332. TOT BIOPHARM
333. TRIO Pharmaceuticals
334. Triphase Accelerator
335. TRITON FUNDS
336. Tubulis
337. UCB
338. University of Copenhagen
339. University of Wisconsin Carbone Cancer Center (UWCCC) 
340. Vaccinex
341. VelosBio (acquired by Merck)
342. Venrock Healthcare Capital Partners
343. Vertex Ventures
344. VI Partners
345. Vida Ventures
346. Viking Global Investors
347. Vir Biotechnology
348. Visterra
349. Vivo Capital
350. Wellington Management
351. WILD Family Office
352. Wild Ventures
353. WS Investments
354. WuXi AppTec (formerly known as WuXi PharmaTech)
355. WuXi Biologics
356. WuXi Healthcare Ventures
357. WuXi STA
358. Xintela
359. Y-Biologics
360. York University
361. Ysios Capital
362. Yuanda China
363. Yuhan Corporation
364. Yunfeng Capital
365. Zhejiang Teruisi Pharmaceutical
366. Zhejiang University Future Capital
367. Zheshang Venture Capital
368. Zymeworks